Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BePharma
Not Confirmed
Contact SupplierBePharma
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
15 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/15/3167271/0/en/Evaluation-of-SON-1010-Using-a-Patient-Derived-Tumoroid-Platform-to-Support-an-Ongoing-Phase-1-Study-in-Patients-with-Sarcoma.html
28 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/28/3016487/0/en/Sonnet-BioTherapeutics-Further-Expands-Global-Intellectual-Property-Portfolio-with-Issuance-of-EU-Patent-for-FHAB-Platform-Technology.html
22 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/22/3013492/0/en/Sonnet-BioTherapeutics-to-Present-at-LIVE-with-Webull-Corporate-Connect-Healthcare-Investment-Webinar.html
21 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/21/3012772/0/en/Sonnet-BioTherapeutics-Expands-Phase-1-SB101-Trial-to-Evaluate-Combination-of-SON-1010-with-Trabectedin-in-Certain-Sarcomas.html
23 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/23/3001288/0/en/Sonnet-BioTherapeutics-Announces-Release-of-the-Next-CEO-Corner-Segment.html
17 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/17/2998294/0/en/Sonnet-BioTherapeutics-Reports-Fiscal-Year-2024-Financial-Results-and-Provides-Corporate-Update.html
Drugs in Development
Details:
Through the licensing deal involving SON-1010, a protein targeting IL-12 receptor, the deal aims to advance treatment for soft tissue sarcoma.
Lead Product(s): SON-1010
Therapeutic Area: Oncology Brand Name: SON-1010
Study Phase: Phase IProduct Type: Protein
Sponsor: Spanios
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2025
Evaluation of SON-1010 in Patient-Derived Tumoroid Platform for Sarcoma Phase 1 Study
Details : Through the licensing deal involving SON-1010, a protein targeting IL-12 receptor, the deal aims to advance treatment for soft tissue sarcoma.
Product Name : SON-1010
Product Type : Protein
Upfront Cash : Inapplicable
October 15, 2025
Details:
SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Lead Product(s): SON-1010,Trabectedin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Lead Product(s) : SON-1010,Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial with Trabectedin in Sarcomas
Details : SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 21, 2025
Details:
The net proceeds from the financing will help the company advance its lead product, SON-1010 (IL12-FHAB), for treating Platinum-resistant Ovarian Cancer.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Chardan
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 09, 2024
Lead Product(s) : SON-1010,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Chardan
Deal Size : $3.9 million
Deal Type : Public Offering
Sonnet BioTherapeutics Announces $3.9M Offering and Nasdaq Private Placement
Details : The net proceeds from the financing will help the company advance its lead product, SON-1010 (IL12-FHAB), for treating Platinum-resistant Ovarian Cancer.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
December 09, 2024
Details:
SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : SON-1010,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonnet BioTherapeutics Announces Topline Safety Data from SON-1010 Monotherapy Phase 1
Details : SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 09, 2024
Details:
Sonnet will use the net proceeds for research and development, including SON-1010, a candidate immunotherapeutic recombinant drug, targeting solid tumors.
Lead Product(s): SON-1010
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Chardan Healthcare
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 06, 2024
Lead Product(s) : SON-1010
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Chardan Healthcare
Deal Size : $5.0 million
Deal Type : Public Offering
Sonnet Prices $5M Public Offering At Market Under Nasdaq Rules
Details : Sonnet will use the net proceeds for research and development, including SON-1010, a candidate immunotherapeutic recombinant drug, targeting solid tumors.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 06, 2024
Details:
Alkem to fund, develop and commercialize SON-080 for the treatment of DPN in India and commercialize SON-080 for the treatment of Chemotherapy Induced Neuropathy and Autonomic Neuropathy in India.
Lead Product(s): Atexakin Alpha
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Alkem Laboratories
Deal Size: $2.0 million Upfront Cash: $1.0 million
Deal Type: Licensing Agreement October 09, 2024
Lead Product(s) : Atexakin Alpha
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Alkem Laboratories
Deal Size : $2.0 million
Deal Type : Licensing Agreement
Sonnet Partners with Alkem to Develop SON-080 For Diabetic Neuropathy
Details : Alkem to fund, develop and commercialize SON-080 for the treatment of DPN in India and commercialize SON-080 for the treatment of Chemotherapy Induced Neuropathy and Autonomic Neuropathy in India.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $1.0 million
October 09, 2024
Details:
SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2024
Lead Product(s) : SON-1010,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonnet Completes Enrollment in Phase 1 Study of SON-1010 for Solid Tumors
Details : SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 18, 2024
Details:
SON-1010 (IL12-FHAB) is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2024
Lead Product(s) : SON-1010,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonnet BioTherapeutics Updates Data for SON-1010 Monotherapy and Combination Therapy
Details : SON-1010 (IL12-FHAB) is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2024
Details:
SON-080 is a low dose recombinant human interleukin-6 (rhIL-6), which is currently being evaluated for the treatment of chemotherapy-induced peripheral neuropathy.
Lead Product(s): Atexakin Alpha
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2024
Sonnet Reports Early Safety Data for SON-080 in Chemotherapy-Induced Neuropathy
Details : SON-080 is a low dose recombinant human interleukin-6 (rhIL-6), which is currently being evaluated for the treatment of chemotherapy-induced peripheral neuropathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 11, 2024
Details:
Sonnet anticipates using the net proceeds from the offering for research and development, including SON-1010 (IL12-FHAB), a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Chardan
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 25, 2023
Lead Product(s) : SON-1010,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Chardan
Deal Size : $4.5 million
Deal Type : Public Offering
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
Details : Sonnet anticipates using the net proceeds from the offering for research and development, including SON-1010 (IL12-FHAB), a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
